Tests Enstilar foam with etanercept or adalimumab for plaque psoriasis
Tests Enstilar foam added to etanercept or adalimumab in adults with psoriasis.
Plain-language title generated from the registry record
Registry title: Enstilar in Combination With Enbrel or Humira for Plaque Psoriasis
Key facts
- Where
- East Windsor, United StatesSee the site
- Phase
- Phase 4
Where in United States
- Psoriasis Treatment Center of Central New JerseyEast Windsor, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Psoriasis Treatment Center of Central New Jersey
- Trial code
- NCT03827876
- Record updated
- 4 February 2019
- Original description
4 weeks of adjunctive therapy of Enstilar® QD followed by 12 weeks QOD to patients with 2-10% BSA who are receiving etanercept or adalimumab for at least 24 weeksRead full original descriptionShow less
An Open-Label Study Evaluating Enstilar® (Calcipotriene and Betamethasone Dipropionate) Foam, 0.005%/0.064% QD in Psoriasis Patients Being Treated With Etanercept or Adalimumab
4 weeks of adjunctive therapy of Enstilar® QD followed by 12 weeks QOD to patients with 2-10% BSA who are receiving etanercept or adalimumab for at least 24 weeks
Inclusion: Male or female adult ≥ 18 years of age; Diagnosis of chronic plaque-type; Patient with 2-10% BSA; Physician Global Assessment of 2 or greater; Patient has been treated with etanercept or adalimumab for a minimum of 24 weeks.
Exclusion: Patient not receiving etanercept or adalimumab, or receiving etanercept or adalimumab <24weeks; ˂2 or >10% BSA; PGA <2.